Losmapimod Safety and Efficacy in COVID-19
Study sponsor: Fulcrum Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-03-31Actual
Enrollment · participants52Actual
Source updated2024-03-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.